BioClinica and Kinapse Partner to Accelerate Risk-Based Monitoring Implementation
NEWTOWN, PENNSYLVANIA, May 21, 2015 – BioClinica®, Inc., a leading specialty clinical trials services and technology provider, today announced it has partnered with Kinapse to accelerate Risk-Based Monitoring (RBM) implementation on global clinical trials using BioClinica’s Compass Intelligent Monitoring solution.
“Implementing a comprehensive RBM solution can make a real difference in clinical research,” BioClinica CEO John Hubbard said. “We’re excited about this collaboration as it helps move the industry forward with intelligent monitoring by bringing together our technology and subject matter expertise with Kinapse’s broad implementation experience.”
Kinapse employs 450 professionals globally and has more than ten years of experience providing strategy and operations consultancy and capability-building programs, including RBM, to life sciences companies.
“In evaluating RBM-enabling technologies, we found BioClinica’s Compass provides one of the most comprehensive solutions,” said Stuart Donald, vice president of advisory services of Kinapse. “Compass is uniquely designed for RBM and has a rich tool set to solve risk and quality issues, making it the right technology in this new era of monitoring.”
Kinapse’s role includes easing the change management process as organizations transition to RBM. “We manage implementation from start to finish, including development of supporting processes,” Donald said.
The partnership comes at a time of increasing demand for Compass and as several pilot studies using the technology show significant improvement in quality and risk reduction. BioClinica’s Vice President of Clinical Innovation, Courtney McBean explained, “Compass catches issues that often go overlooked by onsite monitoring until later in the trial. Finding and fixing issues sooner is less costly and less risky than dealing with bigger problems down the road, especially when it comes to quality and safety.”
BioClinica and Kinapse will make a joint presentation, Essential Steps to Successful Risk-Based Monitoring, on June 4 in Tokyo, Japan.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
